Drug Type Oligonucleotide |
Synonyms- |
Action degraders |
Mechanism MDM2 degraders(p53-binding protein Mdm-2 degraders), NCL degraders(Nucleolin degraders), TYK2 degraders(Tyrosine-protein kinase 2 degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Endocrinology and Metabolic Disease | Discovery | - | 09 Jan 2026 | |
| Immune System Diseases | Discovery | - | 09 Jan 2026 | |
| Neoplasms | Discovery | - | 09 Jan 2026 | |
| Nervous System Diseases | Discovery | - | 09 Jan 2026 | |
| Other Diseases | Discovery | - | 09 Jan 2026 |





